Recombinant human VLDLR Protein, His Tag, 100µg

Background
The very-low-density-lipoprotein receptor (VLDL-R) is a lipoprotein receptor that shows considerable similarity to the lowdensity-lipoprotein receptor. VLDL R is a 130 kDa type I transmembrane protein in the LDL receptor family that plays a significant role in lipid metabolism and in nervous system development and function .This receptor has been suggested to be important for the metabolism of apoprotein-E-containing triacylglycerol-rich lipoproteins, such as very-low-densitylipoprotein (VLDL), beta-migrating VLDL and intermediate-density lipoprotein. It is also one of the receptors of reelin, an extracellular matrix protein which regulates the processes of neuronal migration and synaptic plasticity. In humans, the VLDL-R is encoded by the VLDLR gene.[1]

A rare neurological disorder first described in the 1970s under the name "disequilibrium syndrome" is now considered to be caused by the disruption of VLDLR gene.[2] The disorder was renamed VLDLR-associated cerebellar hypoplasia (VLDLRCH) after a 2005 study.[3] It is associated with parental consanguinity and found in secluded communities such as the Hutterites. VLDLRCH is one of the two known genetic disorders caused by a disruption of reelin signaling pathway, along with Norman-Roberts syndrome.

Source
Human VLDL R, His Tag (VLR-H5227) is expressed from human 293 cells (HEK293). It contains AA Gly 28 - Ser 769 (Accession # P98155-2).
Predicted N-terminus: Gly 28

Molecular Characterization
This protein carries a polyhistidine tag at the C-terminus.
The protein has a calculated MW of 84.0 kDa. The protein migrates as 90-110 kDa under reducing (R) condition (SDS-PAGE) due to different glycosylation.

Endotoxin
Less than 1.0 EU per μg by the LAL method.

Purity
>90% as determined by SDS-PAGE.

Formulation
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4. Normally trehalose is added as protectant before lyophilization.

Reconstitution
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

Storage
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
-20°C to -70°C for 12 months in lyophilized state;
-70^°C for 3 months under sterile conditions after reconstitution.

Bioactivity
Please refer to product data sheet.

Clinical and Translational Updates

(1) "Triglyceride content of lipoprotein subclasses and kidney hemodynamic function and injury in adolescents with type 1 diabetes"
Pauley, Vinovskis, MacDonald et al
J Diabetes Complications (2022) 37 (2), 108384
(2) "Association between Atherogenic Index and Cholesterol to HDL Ratio in COVID-19 Patients During the Initial Phase of Infection"
Taha, Mohialdeen Taha, Al-Obaidy et al
Arch Razi Inst (2022) 77 (3), 1311-1318
(3) "Atorvastatin remodels lipid distribution between liver and adipose tissues through blocking lipoprotein efflux in fish"
Li, Chen, Limbu et al
Am J Physiol Regul Integr Comp Physiol (2022)
Showing 1-3 of 1468 papers.